Aptose Biosciences Inc.
Home
About
Overview
Management Team
Board of Directors
Scientific Advisory Board
Product Pipeline
Overview
Tuspetinib for AML
Luxeptinib for B-cell Tumors
Luxeptinib for Myeloid Tumors
Posters & Presentations
Clinical Trials
Overview
Luxeptinib for CLL & NHL
Luxeptinib for AML
Tuspetinib (HM43239) for AML
Expanded Access
News
Press Releases
Presentations
Events
Investors
Overview
News & Events
Company Info
Financial Info
Stock Data
SEC Filings
SEDAR
Governance
Careers
Contact
Posters & Presentations
Product Pipeline
Product Pipeline
Overview
Tuspetinib for AML
Luxeptinib for B-cell Tumors
Luxeptinib for Myeloid Tumors
Posters & Presentations
All
Poster
Presentation
January 6, 2023
Presentation
Aptose Corporate Presentation January 2023
Aptose Corporate Presentation January 2023:
View Presentation
December 11, 2022
Presentation
Aptose ASH Clinical Update and Data Review
Aptose ASH Clinical Update and Data Review:
View Presentation
December 11, 2022
Poster
2022 ASH Poster - A Phase 1/2 Open-label, Multicenter, Dose Escalation and Expansion Study of the Myeloid Kinase Inhibitor HM43239 (Tuspetinib) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
2022 ASH Poster - A Phase 1/2 Open-label, Multicenter, Dose Escalation and Expansion Study of the Myeloid Kinase Inhibitor HM43239 (Tuspetinib) in Patients with Relapsed or Refractory Acute Myeloid Leukemia:
View Poster
December 11, 2022
Poster
2022 ASH Poster - A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-cell Malignancies
2022 ASH Poster - A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-cell Malignancies:
View Poster
December 11, 2022
Poster
2022 ASH Poster - A Phase 1 a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes
2022 ASH Poster - A Phase 1 a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes:
View Poster
August 19, 2022
Presentation
Aptose Corporate Presentation August 2022
Aptose Corporate Presentation August 2022:
View Presentation
July 19, 2022
Presentation
Aptose Corporate Presentation July 2022
Aptose Corporate Presentation July 2022:
View Presentation
June 27, 2022
Presentation
Aptose Corporate Presentation June 2022
Aptose Corporate Presentation June 2022:
View Presentation
June 10, 2022
Poster
2022 EHA Poster - Myeloid Kinome Inhibitor HM43239 Overcomes Acquired Resistance in Acute Myeloid Leukemia Models
2022 EHA Poster - Myeloid Kinome Inhibitor HM43239 Overcomes Acquired Resistance in Acute Myeloid Leukemia Models:
View Poster
1
2
3
4
5
6
7
Next